Baroreflex Activation Therapy in Heart Failure

Baroreflex Activation Therapy in Heart Failure

The purpose of this clinical investigation is to evaluate the efficacy and safety of the CVRx Barostim Neo System in the treatment of patients with heart failure.

Inclusion Criteria:

• Age at least 21 years
• Symptomatic heart failure despite optimal, stable pharmacological therapy for at least 4 weeks

Exclusion Criteria:

• Significant carotid plaque or stenosis
• Known or suspected baroreflex failure or autonomic neuropathy
• Myocardial infarction, unstable angina, syncope, cerebral vascular accident, SCD, or received defibrillation therapy within the past 3 months
• Heart failure secondary to a reversible condition